CXCR6 and prostate cancer: Our data correlating CXCL16 and CXCR6 with stage and grade of prostate cancer provide additional evidence that, in the prostate, inflammation is tumorigenic, and should stimulate the increasing interest in a possible tumor-promoting role specifically for CD4+ T cells [52].